Legend Biotech Corp (LEGN)

Currency in USD
18.85
-0.19(-1.00%)
Closed·
18.03-0.82(-4.36%)
·
Earnings results expected in 12 days
LEGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
18.7719.37
52 wk Range
16.2440.05
Key Statistics
Prev. Close
18.85
Open
19.2
Day's Range
18.77-19.37
52 wk Range
16.24-40.05
Volume
2.94M
Average Volume (3m)
2.78M
1-Year Change
-53.3531%
Book Value / Share
5.23
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LEGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
52.10
Upside
+176.39%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Legend Biotech Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

11 Buy
4 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 52.10
(+176.39% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy65.00+244.83%-MaintainJul 28, 2026
Raymond James
Buy58.00+207.69%86.00MaintainJul 27, 2026
RBC Capital
Buy59.00+213.00%63.00MaintainJul 27, 2026
UBS
Hold28.00+48.54%49.00DowngradeJul 24, 2026
H.C. Wainwright
Buy65.00+244.83%-MaintainJul 16, 2026

Legend Biotech Corp SWOT Analysis


Carvykti's Triumph
Legend Biotech's flagship product Carvykti drives remarkable 74.75% revenue growth, establishing itself as a leading treatment for multiple myeloma
Financial Fortitude
Explore Legend Biotech's robust liquidity position, with a current ratio of 4.71 and more cash than debt, despite negative EPS
Pipeline Potential
Delve into Legend Biotech's diverse pipeline, including promising CAR-T therapies for gastric, esophageal, and lung cancers, offering growth beyond Carvykti
Market Outlook
Analyst price targets range from $71 to $94, with an average of $82.20, reflecting confidence in Legend Biotech's growth prospects and pipeline potential
Read full SWOT analysis

Legend Biotech Corp Earnings Call Summary for Q1/2026

  • Legend Biotech reported Q1 2026 EPS of -$0.15, missing forecast of $0.01 by 1,600%; revenue reached $305.1M, slightly below expectations.
  • Stock surged 12% pre-market despite earnings miss, driven by strong CARVYKTI sales growth and investor optimism about strategic initiatives.
  • Company projects profitability in 2026 excluding one-time charges; analysts forecast $0.31 EPS for FY2026 and $1.93 EPS by FY2027.
  • Gross margin declined to 41% from 57% in Q4 2025 due to manufacturing expansion costs; expects recovery in Q2 2026 through economies of scale.
  • Strong balance sheet with $835M cash, zero long-term debt; Wall Street maintains Buy rating with $86 price target, suggesting significant upside.
Last Updated: 2026-05-18, 11:32 a/m
Read Full Transcript

Earnings

Latest Release
May 12, 2026
EPS / Forecast
-0.15 / 0.01
Revenue / Forecast
305.1M / 305.88M
EPS Revisions
Last 90 days

LEGN Income Statement

Compare LEGN to Peers and Sector

Metrics to compare
LEGN
Peers
Sector
Relationship
P/E Ratio
−14.6x−1.3x−0.3x
PEG Ratio
0.91−0.050.00
Price/Book
3.8x4.1x2.6x
Price / LTM Sales
3.2x13.0x2.9x
Upside (Analyst Target)
197.1%410.5%56.7%
Fair Value Upside
Unlock24.3%10.2%Unlock

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
38.46M19.88%724.92M
Other Institutional Investors
163.39M80.12%3.08B
Public Companies & Retail Investors
0.000.00%0.00
Total
201.85M100.00%3.8B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Genscript Biotech Corporation45.10%87,248,7781,644,639
FMR LLC13.16%25,466,269480,039

People Also Watch

25.00
RARE
-3.77%
78.39
CYTK
-1.33%
882.56
ARGX
+1.18%
178.18
ICLR
-1.14%
5.41
REPL
+1.12%

FAQ

What Is the Legend Bio (LEGN) Stock Price Today?

The Legend Bio stock price today is 18.85 USD.

What Stock Exchange Does Legend Bio Trade On?

Legend Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Legend Bio?

The stock symbol for Legend Bio is "LEGN."

What Is the Legend Bio Market Cap?

As of today, Legend Bio market cap is 3.65B USD.

What Is Legend Bio's Earnings Per Share (TTM)?

The Legend Bio EPS (TTM) is -1.38.

When Is the Next Legend Bio Earnings Date?

Legend Bio will release its next earnings report on Aug 11, 2026.

From a Technical Analysis Perspective, Is LEGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Legend Bio Stock Split?

Legend Bio has split 0 times.

How Many Employees Does Legend Bio Have?

Legend Bio has 3100 employees.

What is the current trading status of Legend Bio (LEGN)?

As of Jul 30, 2026, Legend Bio (LEGN) is trading at a price of 18.85 USD, with a previous close of 18.85 USD. The stock has fluctuated within a day range of 18.77 USD to 19.37 USD, while its 52-week range spans from 16.24 USD to 40.05 USD.

What Is Legend Bio (LEGN) Price Target According to Analysts?

The average 12-month price target for Legend Bio is 52.10 USD, with a high estimate of 80 USD and a low estimate of 27 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +176.39% Upside potential.

What Is the LEGN Premarket Price?

LEGN's last pre-market stock price is 18.03 USD. The pre-market share volume is 25,220.00, and the stock has decreased by -0.82, or -4.36%.

What Is the LEGN After Hours Price?

LEGN's last after hours stock price is 19.32 USD, the stock has decreased by 0.47, or 2.49%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.